Article Data

  • Views 459
  • Dowloads 134

Original Research

Open Access

iTRAQ-based proteomics analysis reveals novel candidates for platinum resistance of epithelial ovarian cancer

  • Yuanjing Wang1,*,
  • Yumei Wu2

1Department of Radiation Therapy Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Beijing Maternal and Child Health Care Hospital), 100006 Beijing, China

2Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University (Beijing Maternal and Child Health Care Hospital), 100006 Beijing, China

DOI: 10.22514/ejgo.2023.074 Vol.44,Issue 5,October 2023 pp.11-20

Submitted: 18 September 2022 Accepted: 01 February 2023

Published: 15 October 2023

*Corresponding Author(s): Yuanjing Wang E-mail:


Platinum-based chemotherapy is commonly used in the treatment of various cancers, including epithelial ovarian cancer (EOC). However, in EOC, chemotherapy failure is mainly caused by platinum resistance. In this present study, we aimed to identify novel biomarkers for predicting platinum chemosensitivity. Fresh specimens of 16 serous high-grade ovarian cancer (HGSC) cases were collected during cytoreductive surgery. Isobaric tags were used to identify differentially expressed proteins in platinum-resistant samples (n = 8) and platinum-sensitive samples (n = 8). Compared to platinum-sensitive samples, 741 significantly differentially expressed proteins were detected, of which 325 were upregulated and 416 were downregulated. To validate the isobaric tags for relative and absolute quantification (iTRAQ) method, western blotting was performed on two upregulated proteins, angiomotin-like protein 1 (AMOTL1) and Lumican. The results showed that platinum-resistant tumor samples expressed significantly higher levels of AMOTL1 and Lumican than platinum-sensitive tumor samples. Altogether, we identified candidate proteins related to platinum resistance in ovarian cancer. Both AMOTL1 and Lumican seem to be promising biomarkers that could distinguish between platinum-resistant and platinum-sensitive EOC.


Epithelial ovarian cancer; Platinum resistance; Angiomotin-like protein 1; Lumican; Isobaric tags for relative and absolute quantitation

Cite and Share

Yuanjing Wang,Yumei Wu. iTRAQ-based proteomics analysis reveals novel candidates for platinum resistance of epithelial ovarian cancer. European Journal of Gynaecological Oncology. 2023. 44(5);11-20.


[1] Wang X, Xu X, Jiang G, Zhang C, Liu L, Kang J, et al. Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. Journal of Cellular and Molecular Medicine. 2020; 24: 11177–11187.

[2] Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2021; 19: 191–226.

[3] Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews. 2021; 2: CD005343.

[4] van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-Related Cancer. 2018; 25: R303–R318.

[5] Lee H, Kwon OB, Lee JE, Jeon YH, Lee DS, Min SH, et al. Repositioning trimebutine maleate as a cancer treatment targeting ovarian cancer stem cells. Cells. 2021; 10: 918.

[6] Zhu M, Wang J, Wuna Y, Wang Y, Li H. Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46: 644–652.

[7] Vianello C, Cocetta V, Catanzaro D, Dorn GW, De Milito A, Rizzolio F, et al. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy. Cell Death & Disease. 2022; 13: 398.

[8] Dettmer K, Stevens AP, Fagerer SR, Kaspar H, Oefner PJ. Amino acid analysis in physiological samples by GC-MS with propyl chloroformate derivatization and iTRAQ-LC-MS/MS. Methods in Molecular Biology. 2019; 393: 173–190.

[9] Li Y, Guo T, Wang X, Ni W, Hu R, Cui Y, et al. ITRAQ-based quantitative proteomics reveals the proteome profiles of MDBK cells infected with bovine viral diarrhea virus. Virology Journal. 2021; 18: 119.

[10] Swiatly A, Horala A, Matysiak J, Hajduk J, Nowak-Markwitz E, Kokot ZJ. Understanding ovarian cancer: iTRAQ-based poteomics for biomarker discovery. International Journal of Molecular Sciences. 2018; 19: 2240.

[11] Xu S, Wang Y, Li Y, Zhang L, Wang C, Wu X. Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods. Bioscience Reports. 2020; 40: BSR20193075.

[12] Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, et al. MiR-200c sensitizes olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. Journal of Experimental & Clinical Cancer Research. 2020; 39: 3.

[13] Zhou Y, Zhang J, Li H, Huang T, Wong CC, Wu F, et al. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Oncogene. 2020; 39: 4375–4389.

[14] Lv M, Shen Y, Yang J, Li S, Wang B, Chen Z, et al. Angiomotin family members: oncogenes or tumor suppressors? International Journal of Biological Sciences. 2017; 13: 772–781.

[15] Drubin DG, Nelson WJ. Origins of cell polarity. Cell. 1996; 84: 335–344.

[16] Miyoshi J, Takai Y. Structural and functional associations of apical junctions with cytoskeleton. Biochim Biophys Acta. 2008; 1778: 670–691.

[17] Couderc C, Boin A, Fuhrmann L, Vincent-Salomon A, Mandati V, Kieffer Y, et al. AMOTL1 promotes breast cancer progression and is antagonized by Merlin. Neoplasia. 2016; 18: 10–24.

[18] Delgado ILS, Carmona B, Nolasco S, Santos D, Leitão A, Soares H. MOB: pivotal conserved proteins in cytokinesis, cell architecture and tissue homeostasis. Biology. 2020; 9: E413.

[19] Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. Journal of Biological Chemistry. 2011; 286: 7018–7026.

[20] Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene. 2012; 31: 128–134.

[21] Chen X, Li X, Hu X, Jiang F, Shen Y, Xu R, et al. LUM expression and its prognostic significance in gastric cancer. Frontiers in Oncology. 2020; 10: 605.

[22] Di Paolo A, Bocci G. Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification. Current Oncology Reports. 2007; 9: 109–114.

[23] Croix BS, Kerbel RS. Cell adhesion and drug resistance in cancer. Current Opinion in Oncology. 1997; 9: 549–556.

[24] Brézillon S, Untereiner V, Mohamed HT, Ahallal E, Proult I, Nizet P, et al. Label-free infrared spectral histology of skin tissue part II: impact of a lumican-derived peptide on melanoma growth. Frontiers in Cell and Developmental Biology. 2020; 8: 377.

[25] Moseley R, Stewart JE, Stephens P, Waddington RJ, Thomas DW. Extracellular matrix metabolites as potential biomarkers of disease activity in wound fluid: lessons learned from other inflammatory diseases? British Journal of Dermatology. 2004; 150: 401–413.

[26] Neill T, Schaefer L, Iozzo RV. Decoding the matrix: instructive roles of proteoglycan receptors. Biochemistry. 2015; 54: 4583–4598.

[27] Hsiao KC, Chu PY, Chang GC, Liu KJ. Elevated expression of lumican in lung cancer cells promotes bone metastasis through an autocrine regulatory mechanism. Cancers. 2020; 12: 233.

[28] Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, et al. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncology Reports. 2006; 16: 1225–1230.

[29] Klejewski A, Sterzyńska K, Wojtowicz K, Świerczewska M, Partyka M, Brązert M, et al. The significance of lumican expression in ovarian cancer drug-resistant cell lines. Oncotarget. 2017; 8: 74466–74478.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time